Here, we have shown that non homologous end joining is critically important in determining sensitivity to PARP inhibitors. 40% of ovarian cancers tested had defective NHEJ and this rendered them resistant to PARP inhibition, irrespective of their Homologous Recombination status.
Introduction
Double strand breaks (DSBs) [1] , the most lethal forms of DNA damage, are repaired by two main pathways: non-homologous end-joining (NHEJ) and homologous recombination (HR).
These pathways are distinct in that HR copies identical DNA sequences from sister chromatids resulting in error-free repair [2] , whilst NHEJ joins the broken DNA ends with limited processing [3] . In vitro studies have demonstrated that complementary DNA ends are joined in an efficient and accurate manner by NHEJ [4, 5] . However, the modification required for partially or completely incompatible DNA ends results in losses of sequence at the resultant junctions, such that NHEJ is potentially a mutagenic process [3, 6] . More recent studies have demonstrated an alternative end joining mechanism (A-EJ), which uses regions of microhomology at internal sites on the DNA substrate. Unlike HR, A-EJ is inherently error-prone as the use of microhomology leads to deletions of sequences from the strand being repaired, and to chromosomal translocations [7, 8] . This mechanism has been suggested to function in the absence of NHEJ [9] [10] [11] [12] [13] [14] and more recently in absence of HR [7, 8] .
NHEJ has been demonstrated to function throughout the cell cycle [1, 15] . The NHEJ pathway is initiated by the binding of the Ku heterodimer (Ku70 and Ku80) to DSBs, and the subsequent association and autophosphorylation of the DNA-dependent protein kinase catalytic subunit (DNA-PK cs ) [16] . This DNA-PK complex facilitates ligation by recruitment of the XRCC4/LIG4 complex. Mutations in NHEJ components are associated with immunodeficiency and developmental abnormalities [17, 18] as well as cancers [6, [19] [20] [21] [22] , underscoring the importance of the NHEJ pathway in maintaining genome integrity.
DNA damage repair is increasingly recognized as an important determinant of response to cancer therapeutics. This interest was initially provoked by the paradigm shifting discovery that inhibition of base excision repair with Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors (PARPi) was synthetically lethal in HR defective (HRD) tumours. PARPi were therefore selectively targeting the defect arising in the tumour, but not in normal tissues [23] [24] [25] [26] [27] . In epithelial ovarian cancer (EOC) HRD is reported in 50% of cases [28] and evidence is building for the efficacy of PARPi. This has been assumed to be as a result of synthetic lethality, with PARPi preventing effective base excision repair leading to stalled replication forks which in turn could not be repaired by homologous recombination. However a number of studies also indicate a connection between components of the NHEJ pathway and PARP-1 [29] [30] [31] [32] [33] [34] [35] , culminating in the suggestion by Patel et al that dysfunctional NHEJ is important in generating genomic instability in PARPi treated, homologous recombination defective, cells [36] . Moreover, they also demonstrated that inhibition of DNA-PK results in HR function recovery and PARPi resistance in vitro [37] .
The suggestion that NHEJ status is important in determining sensitivity to PARP inhibitors is in keeping with evidence that NHEJ is a fast pathway which is the pathway of choice for the repair of DSBs with HR only being employed for unrepaired DSBs [38] .
The incidence of NHEJ dysfunction has not been explored in primary EOC to date. Here we demonstrate that more than 40% of primary ovarian cancer (PCO) cultures are NHEJ defective (NHEJD), which is associated with resistance to rucaparib ex vivo.
Materials and Methods

Cell culture
Ethical approval was granted (12/NW/0202) for the collection of ascites from consented patients undergoing surgery for EOC at the Queen Elizabeth Hospital, Gateshead, UK.
Clinical details were recorded and specimens registered and handled in accordance with the Human Tissue Act. Samples were assigned a reference number to retain anonymity.
PCO cultures were generated and maintained as previously described [39, 40] . Briefly 20ml of ascites was added to 20ml of warmed Sigma RPMI 1460 HEPES modified culture medium supplemented with 20% v/v fetal calf serum and 100µl/ml penicillin and streptomycin in T75 flasks and incubated at 37°C, 5% CO 2 humidified air.
Cell lines
All cell lines, unless stated otherwise, were grown in RPMI 1640 media supplemented with 10% FBS and 100 units/ml penicillin/streptomycin incubated at 37°C in 5% CO 2. V3 (DNA-PK CS defective) and V3YAC cells (V3 cells complemented with human DNA-PK CS ) were a kind gift from Professor Jeggo. V3YAC cells were grown in full medium with G418 (400 µg/ml). A2780, a human ovarian carcinoma cell line and CP70, MMR deficient variant of A2780, 5-fold resistant to cisplatin relative to the parental A2780 were a kind gift from Prof.
R. Brown (Cancer Research UK Beatson Laboratories, Glasgow, Scotland). SKOV-3, OVCAR-3, IGROV-1, and MDAH are all human ovarian adenocarcinoma cell lines and were purchased from American Type Culture Collection (ATCC, VA, USA). PEO1 cell line was derived from a poorly differentiated serous adenocarcinoma and PEO4 cell line derived from the same patient after clinical resistance developed to chemotherapy. Both were purchased from the European Collection of Cell Cultures.
OSEC2 and OSEC4 cell lines developed at Newcastle University from normal ovarian surface epithelium using a temperature sensitive SV-40 large T antigen construct were incubated at 33 o C [41] .
UWB1-289 is a BRCA1-null human EOC cell line derived from papillary serous ovarian carcinoma was cultured in 50% RPMI 1640 media supplemented with 10% FBS and 100 units/ml penicillin/streptomycin and 50% (v/v) MEBM BulletKit media (Lonza)
supplemented with 10% FBS. UWB1-289-BRCA1 is derived from UWB1-289 cells in which BRCA1 was restored were cultured in full media with 400 µg/ml G418. Both were obtained from American Type Culture Collection.
Cell-free extract preparation
Cell extracts were prepared as previously described [6] . Briefly, three T175 flasks at 80%
confluence were trypsinised, lysed in 500µl of hypotonic buffer and homogenized. After the addition of 0.5 vol of high salt buffer, the extracts were centrifuged for 56 min at 70,000RPM
(213,000g) at 4°C in a Beckman TLA120.2 rotor. Protein concentration was determined using the BSA protein assay according to manufacturer's instructions (ThermoScientific).
Samples were snap-frozen and stored at −80°C.
DNA end-joining assay
Vectors which on digestion with BstXI yielded a 3.2 kb plasmid and 1.2 kb λ fragment with either compatible (Co) (CCACTAAG_GTGG and GGTG_ATTCCACC) or 2 base pair (2I) (CCACTAAG_GTGG and GGTG_AAACCACC) and 4 base pair (4I) (CCACTAAG_GTGG and GGTG_TAAGCACC) incompatible ends. Vectors were kindly donated by Dr Ann Kiltie (Oxford, UK). DNA fragments were gel-purified using spin columns (Qiagen, UK). Endjoining reactions were carried out as previously described [6] with 45 μg protein extract and 100ng DNA substrate for 2.5 hours. DNA was extracted with Tris-buffered phenol/chloroform/isoamyl alcohol. Analysis was performed by agarose (0.7%) gel electrophoresis and GelRed (VWR) staining. Image capture was carried out using G:Box and
GeneSnap system, and analysed using GeneTools (SynGene).
PCR amplification of rejoined products
For the analysis of joined products, end-joining reactions were ethanol-precipitated and amplified using ThermoPrimeTaq with ReadyMix PCR buffer (Thermo Scientific, UK) in the presence of internal plasmid primers pFOR (5′-CCGGCGAACGTGGCGAGAAAG) and pREV (5′-GACTGGAAAGCGGGCAGTGAG) for 40 cycles (30s at 94°C, 30s at 55°C, 30s
at 72°C, full length product size 551 bp). Analysis was performed by agarose (1%) gel electrophoresis and GelRed staining.
Intracellular end joining assay
Plasmid pGL2 (Promega) was linearized using either HindIII or EcoRI, linearization was confirmed by agarose gel electrophoresis. The linearized DNA was purified using the QIAquick PCR Purification Kit, (Qiagen), dissolved in sterilized water, and transfected into cells using Lipofectamine LTX (Invitrogen) as per manufacturer's instructions. The transfectants were harvested 48 hours after transfection and assayed for luciferase activity as described previously [42] .
Homologous recombination assay
Cells were seeded onto glass cover slips and treated with 2 Gy ionising radiation and rucaparib at 10 µM concentration for 24 hours to induce double strand breaks (DSB). All experiments were performed alongside untreated controls with equivalent 0.1% DMSO. Cells were then fixed and rehydrated prior to staining with 1:100 mouse monoclonal anti-γH2AX (Upstate, Millipore Corp., USA) and 1:100 goat polyclonal anti-Rad51 (Calbiochem, EMD Biosciences, Inc., USA) antibodies with appropriate secondary fluorochrome conjugated antibodies, as previously described [43] .
Image J counting software [44, 45] was used to count γH2AX and Rad51 nucleic foci. Cells were classed as homologous recombination (HR) competent if there was more than a 2 fold increase in Rad51 foci after DNA damage, confirmed by a 2 fold increase in γH2AX.
Reverse transcription and real time PCR
Extraction of RNA was performed using an RNeasy Mini kit (Qiagen) as per manufacturer's instructions. RNA was eluted in 30µl RNase-free water and quantified on the Nanodrop ND-1000 Spectrophotometer (Lab tech International). 1.6µg of the total RNA was incubated at 65˚C for 5 min followed by 37˚C for 5 min prior to addition of Promega MMLV-reverse transcriptase master mix (4µl 5x Moloney Murine Leukaemia Virus RT buffer, 2µl 4mM dNTPs, 1µl 50µM Oligo dT15and 0.3µl MMLV reverse transcriptase) and incubation at 37˚C Samples were run on an AbiPrism Applied Biosystems real time PCR machine for 10min at 95˚C, 40 cycles (15s at 95˚C, 60s at 60˚C), 15s at 95˚C, 15s at 60˚C, 15s at 95˚C. Data was analysed using SDS2.3 software.
Gel electrophoresis and western blotting
Western blotting was assessed as previously described [46] . Briefly, 40µg of total protein from each samples was loaded and resolved by electrophoresis in 3-8% SDS-PAGE gradient gels (Biorad), and transferred to nitrocellulose membrane (Hybond C Membrane (GE Healthcare 
SRB assay
Sulforhodamine B (SRB) assay was used to assess cytotoxicity and cell growth as previously described [47] . Briefly, cells were seeded at a concentration of 1000 cells/well and after adherence, treated with different concentrations of rucaparib or cisplatin +/-1µM of DNA-PK inhibitor NU7441 for 10 days before fixation, staining and spectrophotometer assessment.
Immunofluorescence
Immunofluorescence experiments were carried out as previously described [43] . Briefly, cells were fixed after 24 hours with 10 µM rucaparib +/-1 µM NU7441 and 2 Gy X-ray irradiation for HR assay or 1 hour after 2 Gy irradiation for pDNA-PKcs. The ƴH2AX, RAD51 or pDNA-PKcs foci were detected by immunofluorescence using appropriate antibodies. Anti- 
PARP-1 activity
PARP-1 activity was measured using a validated assay as previously described [48] . Briefly, PARP activity in 1000 permeabilised cells was maximally stimulated with a double-stranded oligonucleotide in the presence of excess NAD (350 μM) and the amount of ADP-ribose polymer formed quantified by immunoblot using anti-PAR antibody (clone 10H, from
Professor Dr Alex Burkle University of Konstanz) by reference to a PAR standard curve (Enzo Life Sciences, Exeter, UK). Data is expressed as % PAR of L1210 control.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 6.00 (GraphPad Software, La Jolla California USA) Unpaired student t tests or Mann-Whitney tests were used depending on a D'Agostino & Pearson omnibus normality test. Multiple comparisons were performed using 1-way Anova with Tukeys multiple comparisons correction. All statistical tests were two-sided and considered statistically significant if the P value was less than 0.05.
Results
End-joining accuracy depends on DSB compatibility and NHEJ function
A number of assays are described in the literature to assess NHEJ function [49] . Most of these assays only assess the rejoining of compatible ends, which does not represent the complexity of DNA DSBs that occur in cells. We therefore assessed rejoining of compatible 
DNA end joining in established EOC cell lines
To ensure the cell free extract assay represented the cellular end joining accurately, NHEJ function was assessed in a panel of established cell lines using the cell extract and a cellular luciferase assay (Figure 2 ). Whilst the OSEC cell lines derived from normal ovarian epithelium were able to rejoin 2I ends accurately, four of the six EOC cell lines were unable to rejoin 2I substrates, thus indicating NHEJ deficiency. This correlated with the cellular end joining assay. Mean accurate cellular rejoining rate was 30.17%, 95% confidence interval (CI) = 25-37.6% by cell lines able to rejoin 2I substrates compared to 9.9%, 95% CI 4.39-14.0, p=0.03 by cell lines unable to rejoin 2I substrates, when assessed using the luciferase cellular assay (Pearson correlation r = 0.79 p=0.007). We have previously demonstrated that vector transfection into PCO cultures is not possible [39] , therefore NHEJ was assessed in PCO cultures with the validated extract assay only.
PCO cultures rejoin compatible DSBs, but 40% are unable to rejoin mismatched DSBs
We next assessed end joining in a panel of primary ovarian cancer cultures. PCO cultures had a reduced end joining rate compared to NHEJ competent (NHEJC) control cell lines. There was significant inter-sample variability (range 5% to 39% of loaded DNA, Figure 3 .A-B).
PCR analysis of the junctions formed demonstrated that the rejoining of the Co substrate was accurate (Figure 3 .C).
We found that 20 of the 47 PCO cultures were NHEJD, as demonstrated by incubation with 2I substrates producing either no products, or forming products of significantly smaller size (Example PCR product bands is shown in Figure 3 .C). Furthermore, some cultures formed multiple bands of different sizes indicating loss of differing numbers of nucleotides.
Extensive resection has been demonstrated to be due to use of microhomologies in this vector in the absence of a functional NHEJ pathway [6] . NHEJ competence was seen to be independent of culture growth rate, with a mean doubling time of 117 hours for NHEJC and Table ST1 show that there was no significant difference between the NHEJC and NHEJD cultures in any of the clinical parameters assessed.
hours for NHEJD cultures. Patient characteristics detailed in Supplementary
Sensitivity to rucaparib but not cisplatin is dependent upon competent NHEJ function
Sensitivity of rucaparib and cisplatin was assessed in the cell line panel and all primary cultures. In contrast to HRD association with increased rucaparib sensitivity, NHEJD cultures figure S1) .
Interaction of HR and NHEJ pathways
We have previously demonstrated that 50% of ovarian cultures are functionally HRD [28] , therefore upon the finding that 40% of primary ovarian cancer cultures are also NHEJD we assessed the interaction of NHEJ and HR. The addition of the DNA-PK inhibitor, NU7441, resulted in a significant up-regulation of RAD51 foci after 2Gy irradiation in OSEC2 cells ( Figure 6 .A), demonstrating an increase in HR repair. NU7441 also recovered HR competence in the BRCA1 deficient cell line, but it had no effect in the HR competent or BRCA2 defective cell lines (Figure 6 .B). Furthermore, the mean fold rise in RAD51 foci in DNA-PK deficient M059J cells was significantly higher compared to isogenic DNA-PK proficient M059FUS-1 cells (p < 0.0001, Figure 7 .C).
In our cohort of PCO cultures, NHEJ function was independent of HR competence. 15
cultures were functional for both pathways, 7 cultures were defective for both pathways, while 11 and 14 cultures showed defects in NHEJ and HR respectively. RAD51 foci rise was higher in NHEJD compared to NHEJC cultures (p<0.0024, figure 7 .A). DNA-PKcs expression was higher in HRC cultures compared to HRD cultures (p<0.0001, figure 7 .A).).
When taking both HR and NHEJ function into account, whilst both NHEJC/HRC and NHEJD/HRC were found to have RAD51 foci fold rise >2, the mean RAD51 foci fold rise for NHEJC/HRC group was lower compared to NHEJD/HRC group (Figure 7 .B). The differences in RAD51 foci rise between all four groups was independent of the amount of DNA DSBs, as determined by ƴH2AX foci formation. Importantly , no correlation between either PARP-1 activity or mRNA expression and HR or NHEJ competence was found (Supplementary figure 1.C).
Discussion
Here we have described our findings that NHEJ is defective in more than 40% of ex vivo The sensitivity of HRD cancers to PARPi was initially attributed to the concept of synthetic lethality, based on the theory that HR defective cells are unable to repair DNA DSBs [25, 52] . However, the majority of DNA DSBs are repaired by NHEJ [1, 15] . Furthermore, cell line studies demonstrate interaction between the NHEJ pathway, PARP-1 and subsequent resistance to PARPi [37] . The suggested role for NHEJ in PARPi sensitivity was through up regulation of error prone NHEJ in HRD cells [37] . Recent studies have demonstrated that the error prone A-EJ, functions in the absence of NHEJ and competes with HR [7, 8, 53] . Clearly the interaction between the various DSB repair pathways is complex and understanding is compounded by the commonality of the early part of the process. In this study we weren't able to assess the cell cycle specific of both pathways but this may provide further insight into the interaction [54] .
Nevertheless,we have found that NHEJ function is independent of HR competence and that inhibition of NHEJ resulted in up regulation of HR function in HRC and BRCA1 deficient cells. In our cohort, the cultures which were NHEJD were resistant to rucaparib, irrespective of HR function. This is supported by the observation that NU7441 caused rucaparib resistance in all sensitive cultures, independent of HR function. When taking both pathways into account only NHEJC/HRD cultures were found to be sensitive to rucaparib. Here we demonstrate the role of NHEJ function in ex vivo primary cultures. Therefore, we propose that in EOC, in the absence of HR, error prone NHEJ results in sensitivity to PARPi.
Conversely absence of NHEJ function results in PARPi resistance in HRD cells. This may be through A-EJ, however assessment of this pathway in primary EOC is still needed. Due to the inhibitory effect of cisplatin on NHEJ [55] , this model is limited to rucaparib sensitivity only.
The hypothesis put forward for the role of NHEJ in PARPi resistance is based on the error proneness of NHEJ. The errors in repair are suggested to cause lethal defects in DNA, which, in the absence of HR, results in apoptosis. Therefore, NHEJC/HRD cells are sensitive to
PARPi. Cells with competent NHEJ and HR pathways are able to repair DNA damage and are, therefore, resistant to PARPi. In the absence of NHEJ, the slower error free HR takes over repair. This notion is supported by findings of greater HR function, demonstrated by greater RAD51 foci formation in the DNA-PK deficient cell lines in this study as well as the existing literature [56] . Therefore, in the absence of NHEJ function, the lack of error prone repair results in resistance to PARPi [37] .
Our finding of selectivity for a DNA-PKcs inhibitor to selectively revert the BRCA1 mutant The role of BRCA2 is within HR pathway itself. Therefore inhibiting NHEJ in the absence of BRCA2 still does not activate HR because HR itself is broken.
The ability to select the correct patient, for the correct treatment, at the right time, is required for personalised medicine. Our findings suggest that accurate selection will be compromised if HR function alone is assessed and assessment of NHEJ may also be required. Whilst attempts are being made to develop predictive biomarkers of HR, we suggest that biomarkers for NHEJ should also be developed in order to aid patient selection for PARPi therapy. 
